Disease · MONDO_0019060
bone neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. bone neoplasm. Diseases, record MONDO_0019060. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019060
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
BONE NEOPL, NEOPL BONE, Neoplasm, Bone, Neoplasms, Bone, bone neoplasms, bone tissue neoplasm, bone tissue tumor, bone tissue tumour, bone tumor, bone tumors, bone tumour, bone tumours, neoplasm of bone, neoplasm of bone tissue, neoplasm of the bone, osseous neoplasm, osseous tumor, osseous tumour, tumor of bone, tumor of bone tissue, tumor of the bone, tumour of bone, tumour of bone tissue, tumour of the bone
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 10 drugs, from EMA Human Drugs and PMDA
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DENOSUMAB | CHEMBL1237023 | Antibody | Approval | EMA Human Drugs | 14 | 0 | 0 | Drugs and targets |
| DOXORUBICIN HYDROCHLORIDE | CHEMBL359744 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| LIDOCAINE | CHEMBL79 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CATEQUENTINIB | CHEMBL4303201 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CELECOXIB | CHEMBL118 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| THALIDOMIDE | CHEMBL468 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Approval | https://conductscience.org/library/genes/7153 | Drugs and targets |
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 2 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 2 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 1 | CRL4(CRBN) E3 ubiquitin ligase inhibitor | Phase 2 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor 3 | 1 | Vascular endothelial growth factor receptor 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor 2 | 1 | Vascular endothelial growth factor receptor 2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 1 | Stem cell growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 1 | Platelet-derived growth factor receptor beta inhibitor | Phase 2 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor alpha | 1 | Peroxisome proliferator-activated receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| PTGS2 | Prostaglandin G/H synthase 2 | 1 | Cyclooxygenase-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/5743 | Drugs and targets |
1 to 10 of 23
See all 23 targetsTrials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | Phase 2 | 101 | 2014-09-09 | Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific | CELECOXIB, CYCLOPHOSPHAMIDE, ETOPOSIDE, FENOFIBRATE, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04741880 | Evaluation of Intravenous Lidocaine and Time to Regression of the Sensory Block After Spinal Anesthesia (ELSA Trial) | Phase 2/3 | 66 | Anesthesia, Cancer | LIDOCAINE, SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03527888 | Study of Anlotinib in Patients With Primary Malignant Bone Tumors | Phase 2 | 40 | Neoplasm of Bone | CATEQUENTINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials0
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
None in this release.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019060
GET https://conductscience.org/api/diseases/v1/MONDO_0019060/targets?page=2